hackint0sh/New-Dataset huggingface dataset:
* Fitness level conditions: Bariatric Surgery Candidate studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: In accordance with a parallel study design, 30 pre-bariatric-surgery patients will be randomized in a 1:1 ratio to either undergo 8-weeks of pre-operative standard of care or 8-weeks of pre-operative standard of care plus moderate exercise prior to undergoing bariatric-surgery. Randomization scheme: The randomization will be generated utilizing a permuted block randomization scheme in which 5 blocks of 6 treatment assignments (3 per treatment) will be generated via a computer algorithm. The 6 treatment assignments of each block will be listed in random sequential order and the treatment assignments will be assigned according to the random sequential order. The randomization will be generated by our biostatistician. primaryPurpose: SUPPORTIVE_CARE masking: NONE maskingDescription: Randomization will be completely random and will only be known by biostatistician and study coordinator in department but not on study to retain true randomization unaffected by study team. count: 30 type: ESTIMATED name: Exercise Group measure: Insulin sensitivity measure: Surgical outcomes - readmission within 30 days of surgery measure: Surgical outcomes - IV treatment as an outpatient measure: Surgical outcomes - emergency department visits measure: Surgical outcomes - time of surgery measure: Surgical outcomes - length of stay after surgery completion measure: Flow-mediated dilation (FMD) measure: Pulse-wave analysis (PWA) measure: Pulse-wave velocity (PWV) measure: Body fat measure: Lean body mass measure: Bone mineral density measure: Visceral adiposity measure: Weight measure: Blood Lipids measure: Plasma glucose measure: Plasma insulin measure: Hemoglobin A1c measure: Cardiorespiratory fitness measure: Quality of life (SF-36) sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: University of Virginia city: Charlottesville state: Virginia zip: 22902 country: United States name: Damon L Swift, PhD role: CONTACT phone: 434-924-1436 email: dls3s@virginia.edu name: Emily E Grammer, MS role: CONTACT phone: 8508968401 email: erk9nk@virginia.edu lat: 38.02931 lon: -78.47668 hasResults: False
nctId: NCT06274593 id: AP_JBD_MJ_003 briefTitle: Study of OCT Peripapillary Angiography in Patients With Advanced Glaucoma acronym: OGA overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2027-04 date: 2027-09 date: 2024-02-23 date: 2024-02-23 name: Nantes University Hospital class: OTHER briefSummary: Glaucoma is a chronic disease of the optic nerve, characterized by progressive loss of nerve cells in the retina, leading to progressive loss of peripheral and central vision. There are in fact several types of glaucoma, which is the world's second leading cause of blindness after cataracts, and the leading cause of irreversible blindness.
The main aim of this study is to compare the 3-year progression rate of 3 examinations in advanced glaucoma patients: one functional (visual field) and two anatomical (OCTa and OCTrnfl). conditions: Glaucoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: OCT measure: Compare the progression of vascular density (VD) in advanced glaucoma patients. measure: Compare the progression of peripapillary retinal nerve fiber (RNFL) thickness) in advanced glaucoma patients. measure: Compare the progression of visual field in advanced glaucoma patients. measure: CV-OCTrnfl correlation study and CV-OCTa correlation study on measurements made at inclusion and on measurements made during follow-up sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Jean-Baptiste Ducloyer city: Nantes zip: 44093 country: France name: Jean-Baptiste Ducloyer, MD role: CONTACT email: jeanbaptiste.ducloyer@chu-nantes.fr lat: 47.21725 lon: -1.55336 hasResults: False
nctId: NCT06274580 id: 5916 briefTitle: Endovascular vs Conservative Treatment in Patients With Chronic Subdural Hematomas and Mild Symptoms overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-03-01 date: 2026-03-01 date: 2024-02-23 date: 2024-02-23 name: Ospedale Policlinico San Martino class: OTHER briefSummary: Embotrial-1 is an Italian multicenter prospective randomized clinical trial with open-label treatment and blinded outcome assessment (PROBE) to assess the superiority of MMA embolization compared to conservative treatment. The intervention group is MMA embolization and comparator control group is the conservative management with best medical treatment. Patients are randomized 1:1. conditions: Subdural Hematoma, Chronic studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 300 type: ESTIMATED name: embolization of the middle meningeal artery measure: Rate of incomplete hematoma resolution or surgical rescue measure: treatment complication measure: treatment successful sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06274567 id: 2024P000348 briefTitle: Intermittent Theta Burst Stimulation (iTBS) for Emotion Regulation in Bipolar Disorder overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2028-08-31 date: 2029-03-31 date: 2024-02-23 date: 2024-02-23 name: Massachusetts General Hospital class: OTHER name: University of Pennsylvania briefSummary: The objective of this study protocol is to test whether intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) to the inferior parietal lobule (IPL) can strengthen functional connectivity with a key region in emotion regulation (ER) neurocircuitry (anterior insula, AI) and improve performance on ER-related tasks in patients with bipolar disorder. Individual IPL sites for stimulation will be identified through baseline, pre-TMS functional magnetic resonance imaging (fMRI) scans. Patient-specific IPL subregions showing positive functional connectivity with the anterior insula and falling within the patient-specific frontoparietal control network will be used as individualized target sites for TMS stimulation. Patients will be randomized to receive 24 sessions of active versus sham iTBS to patient-specific IPL targets (6 sessions/day, 4 days, 43,200 pulses total). Post-iTBS resting-state and task-based fMRI scans will be acquired 3 days after the final day of iTBS administration (Day 4) following identical procedures as baseline. Effects of iTBS-TMS on ER will be evaluated by comparing pre-TMS versus post-TMS functional connectivity and behavior during performance on ER tasks. conditions: Bipolar Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized allocation primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: We will use an active/placebo TMS coil. TMS operator and participant will be blinded to active versus sham. Investigator will be blinded to participant condition assignment. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 136 type: ESTIMATED name: Transcranial Magnetic Stimulation (TMS) name: Sham (placebo) TMS measure: Correlated functional magnetic resonance imaging (fMRI) time series (functional connectivity) measure: Affective Multisource Interference Task measure: Balloon Analogue Risk Task sex: ALL minimumAge: 24 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Martinos Center for Biomedical Imaging city: Charlestown state: Massachusetts zip: 02129 country: United States lat: 42.37787 lon: -71.062 hasResults: False
nctId: NCT06274554 id: 23-11026746 briefTitle: Testing the Role for Anti-fungal Therapy in Improving the Response to Medicine for Crohn's Disease overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2028-12 date: 2029-12 date: 2024-02-23 date: 2024-02-23 name: Weill Medical College of Cornell University class: OTHER name: The Leona M. and Harry B. Helmsley Charitable Trust briefSummary: The goal of this clinical trial is to learn about the effects of fluconazole in patients who plan to or are undergoing standard of care treatment with an IL-23 therapy for their Crohn's disease.
The main question it aims to assess is will patient response to IL-23 therapies improve when simultaneously treated with fluconazole. conditions: Crohn's Disease conditions: Inflammatory Bowel Diseases studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Double-blinded study whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 120 type: ESTIMATED name: Fluconazole name: Placebo name: IL-23 Therapy measure: Proportion of subjects achieving clinical response measure: Proportion of subjects achieving clinical remission measure: Proportion of patients achieving endoscopic response or remission sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Weill Cornell Medicine city: New York state: New York zip: 10065 country: United States name: Grace Xiang, BS role: CONTACT phone: 646-697-0985 email: grx4001@med.cornell.edu name: Randy Longman, MD, PhD role: PRINCIPAL_INVESTIGATOR name: Dana Lukin, MD, PhD role: SUB_INVESTIGATOR name: Ellen Scherl, MD role: SUB_INVESTIGATOR name: Iliyan Iliev, PhD role: PRINCIPAL_INVESTIGATOR lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06274528 id: 202301150 briefTitle: DORA and LP in Alzheimer's Disease Biomarkers overallStatus: RECRUITING date: 2024-03-11 date: 2029-03-11 date: 2029-03-11 date: 2024-02-23 date: 2024-03-29 name: Washington University School of Medicine class: OTHER briefSummary: The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the fluid around the brain known as cerebrospinal fluid (CSF). Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer's disease. conditions: Alzheimer Disease studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Pharmacist whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 201 type: ESTIMATED name: Lemborexant 10 mg name: Lemborexant 20mg name: Placebo measure: Changes CSF pT181/T181 ratio of lemborexant 10 and 20 mg compared to Placebo measure: Number of participants with treatment-related adverse events measure: Measure the blood concentration of lemborexant 10 mg and 20 mg and determine the dose-response relationship with CSF pT181/T181 measure: Measure changes on blood plasma amyloid-beta isoforms (Aβ38, Aβ40, Aβ42) measure: Measure changes of CSF amyloid beta isoforms (Aβ38, Aβ40, Aβ42) measure: Measure changes of blood plasma p-tau/tau forms (T181, pT181, S202, pS202, pS202/S202, T217, pT217, pT217/T217). measure: Measure changes of cerebrospinal fluid p-tau/tau forms (T181, pT181, S202, pS202, pS202/S202, T217, pT217, pT217/T217). measure: Measure changes of cerebrospinal TREM2 (exploratory) measure: Measure changes of cerebrospinal NPTX2 (exploratory) measure: Measure changes of cerebrospinal NfL (exploratory) measure: Measure changes of blood plasma NfL (exploratory) sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: Washington University in St. Louis, School of Medicine status: RECRUITING city: Saint Louis state: Missouri zip: 63110 country: United States name: Cristina Toedebusch, BS role: CONTACT phone: 314-747-0646 email: toedebuschc@wustl.edu name: Chloe Meehan, BS, MA role: CONTACT phone: 314-273-0878 email: cmeehan@wustl.edu name: Brendan P. Lucey, M.D. role: PRINCIPAL_INVESTIGATOR name: J. Philip Miller, Ph.D. role: SUB_INVESTIGATOR name: Jason Hassenstab, Ph.D. role: SUB_INVESTIGATOR name: David Carr, M.D. role: SUB_INVESTIGATOR lat: 38.62727 lon: -90.19789 hasResults: False
nctId: NCT06274515 id: WO44977 briefTitle: A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies acronym: REMERGE overallStatus: RECRUITING date: 2024-04-02 date: 2027-01-28 date: 2027-01-28 date: 2024-02-23 date: 2024-04-08 name: Hoffmann-La Roche class: INDUSTRY briefSummary: This study will evaluate mechanisms of resistance to anti-breast cancer therapies in tumor and blood samples from participants with human epidermal growth factor receptor (HER2) positive, hormone receptor (HR) positive or triple negative breast cancer. conditions: Breast Cancer studyType: INTERVENTIONAL phases: PHASE4 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 320 type: ESTIMATED name: Tumor Tissue and Blood Draw measure: Changes from baseline in HER2 protein levels measured at the time of disease progression/recurrence (Cohorts H1 and H2) measure: Changes from baseline in HER2 gene copy number measured at the time of disease progression/recurrence (Cohorts H1 and H2) measure: Changes from baseline in estrogen receptor (ER) protein levels measured at the time of disease progression/recurrence (Cohorts H1 and H2) measure: Changes from baseline in HER2 protein levels measured at the time of disease progression/recurrence (Cohort H3) measure: Changes from baseline in HER2 gene copy number measured at the time of disease progression/recurrence (Cohort H3) measure: Changes from baseline in ER protein levels measured at the time of disease progression/recurrence (Cohort H3) measure: Changes from baseline in genes related to CDK4/6 resistance (incl. cell cycle alterations and tyrosine kinase receptors, Cohort R1) measure: Changes from baseline in genes related to endocrine resistance (incl. cell cycle alterations and tyrosine kinase receptors, Cohort R1) measure: Changes from baseline in tumor immune microenvironment (PD-L1 and TILs, Cohort T1) measure: Changes from baseline in immune phenotype (PD-L1 and TILs, Cohort T1) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: KEM/Evang. Kliniken Essen Mitte gGmbH; Klinik für Internistische Onkologie / Hämatologie status: RECRUITING city: Essen zip: 45136 country: Germany lat: 51.45657 lon: 7.01228 facility: I.R.S.T Srl IRCCS; Oncologia Medica status: RECRUITING city: Meldola state: Emilia-Romagna zip: 47014 country: Italy lat: 44.12775 lon: 12.0626 facility: Fondazione Policlinico Universitario Agostino Gemelli IRCCS status: RECRUITING city: Rome state: Lazio zip: 00168 country: Italy lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06274502 id: deep learning briefTitle: Automated Detection and Diagnosis of Pathological DRGs in PHN Patients Using Deep Learning and Magnetic Resonance overallStatus: COMPLETED date: 2023-10-01 date: 2024-01-31 date: 2024-01-31 date: 2024-02-23 date: 2024-03-06 name: Huazhong University of Science and Technology class: OTHER briefSummary: Here, this study aimed to develop an automated system for detecting and diagnosing lesion DRGs in PHN patients based on deep learning. This study retrospectively analyzed the DRG images of all patients with postherpetic neuralgia who underwent magnetic resonance neuroimaging examinations in our radiology department from January 2021 to February 2022. After image post-processing, the You Only Look Once (YOLO) version 8 was selected as the target algorithm model. Model performance was evaluated using metrics such as precision, recall, Average Precision, mean average precision and F1 score. conditions: Deep Learning studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 41 type: ACTUAL name: YOLOv8 measure: Develop an automated system for detecting and diagnosing lesion DRGs in PHN patients based on deep learning sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology city: Wuhan state: Hubei zip: 430030 country: China lat: 30.58333 lon: 114.26667 facility: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology city: Wuhan country: China lat: 30.58333 lon: 114.26667 hasResults: False
nctId: NCT06274489 id: GSN000500 briefTitle: A Study to Evaluate Setanaxib in Patients With Alport Syndrome overallStatus: RECRUITING date: 2023-11-27 date: 2025-01-27 date: 2025-01-27 date: 2024-02-23 date: 2024-04-05 name: Calliditas Therapeutics AB class: INDUSTRY briefSummary: The purpose of the study is to learn about the safety and tolerability of setanaxib in subjects with Alport syndrome, when added to their standard of care treatment. The study will assess how safe setanaxib is when compared to placebo. Study participants will be asked if they are experiencing any side effects at each study visit. In addition, tests in blood, urine and other examinations will be used to look at the safety of setanaxib. The study will also measure how well setanaxib works in comparison to a placebo, by measuring urine protein and certain markers in the blood and urine. The concentration of setanaxib in the blood will also be measured throughout the course of the study.
nctId: NCT06274476 id: 2020/9/9 briefTitle: Prosthetic Rehabilitation of Thin Wiry Ridge by Ridge Splitting and Simultaneous Implants Placement acronym: implant overallStatus: COMPLETED date: 2018-09-09 date: 2019-12-09 date: 2020-01-01 date: 2024-02-23 date: 2024-02-23 name: Cairo University class: OTHER briefSummary: evaluates the success of prosthetic rehabilitation of thin wiry ridge and implants placed simultaneously in splitted ridge both clinically and radiographically. conditions: Atrophic Maxillary Ridge and Mandibular Ridge studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: maxillary and mandibular atrophic ridge primaryPurpose: OTHER masking: DOUBLE maskingDescription: double whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 21 type: ACTUAL name: implant placement measure: implant success sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Mohamed yahia Sharaf city: Zagazig state: Sharkia zip: 44715 country: Egypt lat: 30.58768 lon: 31.502 hasResults: False
nctId: NCT06274463 id: 2023-11-035 briefTitle: A Personalized Trunk Stability Exercise Program Study With Brain Disease Patients overallStatus: NOT_YET_RECRUITING date: 2024-02-21 date: 2024-12-31 date: 2024-12-31 date: 2024-02-23 date: 2024-02-23 name: Bundang CHA Hospital class: OTHER briefSummary: To investigate the effect on improving trunk stability and satisfaction with the program when a customized trunk stabilization exercise program personalized to the subject's functional level is applied to patients with brain disease. conditions: Brain Diseases studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Exercise therapy including a trunk stabilization exercise program measure: Trunk Impairment Scale measure: Berg Balance Scale measure: Joint angle measure: Joint moment measure: Joint power sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06274450 id: C2202112 briefTitle: A Clinical Study on the Improvement of Skin and Living Conditions After Drinking Rosa Roxburghii and Pomegranate Drinks overallStatus: COMPLETED date: 2022-07-06 date: 2022-09-02 date: 2022-09-02 date: 2024-02-23 date: 2024-02-23 name: Botanee Group Co., Ltd. class: INDUSTRY briefSummary: The main objective of the study is to observe changes in the subjects' skin condition and life status after 8 weeks of drinking rosa roxburghii and pomegranate drinks.
This is a single-center, randomized, single-blind, controlled, 8-week (56-day) clinical study conducted in Chinese healthy women aged 25-45 years old who were offered a rosa roxburghii and pomegranate drink. conditions: Skin Laxity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 70 type: ACTUAL name: skin care product name: Drinks with active ingredients Rosa Roxburghii and Pomegranate measure: Changes in the skin hydration measure: Changes in the skin glossiness measure: Changes in the skin firmness measure: Changes in the skin elasticity measure: Changes in the individual type angle measure: Changes in the melanin content measure: Changes in the proportion of crow's feet area measure: Changes in the proportion of fine lines under the eye measure: Changes in the CIE RGB of skin tone measure: Changes in the grade of Pigmentation measure: Skin condition Assessment after 4-week application measure: Skin condition Assessment after 8-week application measure: Changes in the satisfaction with the quality of life sex: FEMALE minimumAge: 25 Years maximumAge: 45 Years stdAges: ADULT facility: Shanghai China-norm Quality Technical Service Co ，Ltd city: Shanghai state: Shanghai zip: 200072 country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06274424 id: HUS/211/2016 and HUS/2699/2018 briefTitle: Hair Cortisol and Symptoms in Children With Psychopathology During CBT overallStatus: COMPLETED date: 2016-07-01 date: 2019-10-01 date: 2019-10-01 date: 2024-02-23 date: 2024-02-29 name: Helsinki University Central Hospital class: OTHER briefSummary: This study aims to examine the relationship between hair cortisol concentration and behavior and sleep disturbance symptoms in children with psychiatric disorders. It also investigates potential changes in hair cortisol and symptomatology after group-based cognitive behavior therapy. Furthermore, the study explores the effects of any alterations in hair cortisol concentration levels on potential behavior and sleep disturbance symptom change over the course of the study. conditions: Child Behavior Problem studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 100 type: ACTUAL name: The Friends Program measure: Hair Cortisol Concentration measure: Parent- and teacher rated internalizing and externalizing symptoms measure: Child-rated internalizing symptoms measure: Parent-rated sleep disturbance symptoms sex: ALL minimumAge: 6 Years maximumAge: 13 Years stdAges: CHILD hasResults: False
nctId: NCT06274411 id: KS2024014 briefTitle: Standby Cannulated ECMO for High-Risk Percutaneous Coronary Intervention acronym: ESCORT overallStatus: RECRUITING date: 2024-03-01 date: 2025-12-31 date: 2026-03-01 date: 2024-02-23 date: 2024-02-23 name: Beijing Anzhen Hospital class: OTHER briefSummary: The goal of this multicenter, randomized trial is to compare standby cannulated ECMO versus prophylactic ECMO in patients undergoing high-risk percutaneous coronary intervention (PCI). The main question it aims to answer is :
• If standby cannulated ECMO as compared with prophylactic ECMO will improve the outcomes in patients undergoing high-risk PCI conditions: ECMO conditions: High-risk PCI studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 176 type: ESTIMATED name: Standby cannulated ECMO name: Prophylactic ECMO measure: Composite rate of 8 major adverse events measure: Platelet drop measure: Duration of ECMO support measure: Length of hospital stay measure: Hemoglobin drop measure: Serum interleukin-6 concentration sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Anzhen Hospital status: RECRUITING city: Beijing state: Beijing zip: 100029 country: China name: Liangshan Wang, MD role: CONTACT phone: 86-13811363372 email: wangliangshanbam@sina.com lat: 39.9075 lon: 116.39723 hasResults: False